PD-L1 (RBT-PDL1) Rabbit
PD-L1 (RBT-PDL1) Rabbit
| Application | IHC |
| Clone | RBT-PDL1 |
| Conjugué | Unconjugated |
| Conseil | |
| Couleur | |
| Hôte | Rabbit |
| Immunogène | Synthetic peptide corresponding to N-terminus residues of the human PD-L1 protein |
| Isotype | IgG |
| Localisation | Membranous |
| Pathologie | Lymphoma, Hodgkin's and NHD Lymphoma, Lung Cancer, Melanoma, Kidney, Urotelial Cancer, Ovarian Cancer, Immunotherapy |
| Predicted reactivity | |
| Purification | |
| Réactivité | Human |
| Spécificité | |
| Taille | |
| Tissus controles | Tonsil, Placenta, Lymphoblastic Lymphoma |
Prêt à l'emploi
| Conditionnement | Reference | Supplier | Certification | Dilution | TDS | Quantity |
|---|---|---|---|---|---|---|
| 7 ml | BSB2650 |
|
IVD/CE | RTU |
|
|
| 15 ml | BSB2651 |
|
IVD/CE | RTU |
|
|
| 3 ml | BSB2649 |
|
IVD/CE | RTU |
|
Concentré
| Conditionnement | Reference | Supplier | Certification | Dilution | TDS | Quantity |
|---|---|---|---|---|---|---|
| 0,5 ml | BSB2653 |
|
IVD/CE | 1/25 - 1/100 |
|
|
| 0,1 ml | BSB2652 |
|
IVD/CE | 1/25 - 1/100 |
|
|
| 1 ml | BSB2654 |
|
IVD/CE | 1/25 - 1/100 |
|
Control Slides
| Conditionnement | Reference | Supplier | Certification | Dilution | TDS | Quantity |
|---|---|---|---|---|---|---|
| 5 slides | BSB2655 |
|
IVD/CE |
|
||
| 5 slides | BSB9339-CS |
|
IVD/CE |
|